Kailera Therapeutics priced its upsized initial public offering at the $16 high-end on April 16, raising a record $625 million—the largest biotech IPO of 2026—implying a fully diluted valuation exceeding $2.1 billion and setting the stage for trader consensus on the 2.1B+ outcome. Shares debuted strongly on Nasdaq (KLRA) April 17, closing at $26 amid 63% first-day gains on 8 million shares traded, pushing market capitalization to $3.07 billion based on official outstanding shares. This reflects robust demand for the company's Phase 3 obesity candidate ribupatide, a once-weekly GLP-1/GIP, amid GLP-1 sector hype and open biotech IPO windows. Polymarket's skin-in-the-game crowd prices near-certainty here, though rare post-debut adjustments to filings or abbreviated trading could theoretically challenge it; settlement is expected April 20.
Résumé expérimental généré par IA à partir des données Polymarket. Ceci n'est pas un conseil de trading et ne joue aucun rôle dans la résolution de ce marché. · Mis à jour2.1B+ 99.4%
1.8B–1.9B <1%
2.0B–2.1B <1%
1.9B–2.0B <1%
$26,612 Vol.
$26,612 Vol.
17 avr. 2026
1.8B–1.9B
1%
1.9B–2.0B
<1%
2.0B–2.1B
1%
2.1B+
99%
2.1B+ 99.4%
1.8B–1.9B <1%
2.0B–2.1B <1%
1.9B–2.0B <1%
$26,612 Vol.
$26,612 Vol.
17 avr. 2026
1.8B–1.9B
$2,327 Vol.
1%
1.9B–2.0B
$2,633 Vol.
<1%
2.0B–2.1B
$2,939 Vol.
1%
2.1B+
$13,205 Vol.
99%
This market will resolve based on Kailera Therapeutics’ market capitalization at the closing price on its first day of trading.
As of market creation, the IPO is scheduled to price on April 17 (ET). If no such IPO occurs by May 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before June 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.Kailera Therapeutics priced its upsized initial public offering at the $16 high-end on April 16, raising a record $625 million—the largest biotech IPO of 2026—implying a fully diluted valuation exceeding $2.1 billion and setting the stage for trader consensus on the 2.1B+ outcome. Shares debuted strongly on Nasdaq (KLRA) April 17, closing at $26 amid 63% first-day gains on 8 million shares traded, pushing market capitalization to $3.07 billion based on official outstanding shares. This reflects robust demand for the company's Phase 3 obesity candidate ribupatide, a once-weekly GLP-1/GIP, amid GLP-1 sector hype and open biotech IPO windows. Polymarket's skin-in-the-game crowd prices near-certainty here, though rare post-debut adjustments to filings or abbreviated trading could theoretically challenge it; settlement is expected April 20.
This market will resolve based on Kailera Therapeutics’ market capitalization at the closing price on its first day of trading.
As of market creation, the IPO is scheduled to price on April 17 (ET). If no such IPO occurs by May 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before June 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
As of market creation, the IPO is scheduled to price on April 17 (ET). If no such IPO occurs by May 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before June 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
Marché ouvert : Apr 14, 2026, 5:05 PM ET
Volume
$26,612Date de fin
17 avr. 2026Marché ouvert
Apr 14, 2026, 5:05 PM ETResolver
0x69c47De9D...This market will resolve based on Kailera Therapeutics’ market capitalization at the closing price on its first day of trading.
As of market creation, the IPO is scheduled to price on April 17 (ET). If no such IPO occurs by May 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before June 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.Kailera Therapeutics priced its upsized initial public offering at the $16 high-end on April 16, raising a record $625 million—the largest biotech IPO of 2026—implying a fully diluted valuation exceeding $2.1 billion and setting the stage for trader consensus on the 2.1B+ outcome. Shares debuted strongly on Nasdaq (KLRA) April 17, closing at $26 amid 63% first-day gains on 8 million shares traded, pushing market capitalization to $3.07 billion based on official outstanding shares. This reflects robust demand for the company's Phase 3 obesity candidate ribupatide, a once-weekly GLP-1/GIP, amid GLP-1 sector hype and open biotech IPO windows. Polymarket's skin-in-the-game crowd prices near-certainty here, though rare post-debut adjustments to filings or abbreviated trading could theoretically challenge it; settlement is expected April 20.
This market will resolve based on Kailera Therapeutics’ market capitalization at the closing price on its first day of trading.
As of market creation, the IPO is scheduled to price on April 17 (ET). If no such IPO occurs by May 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before June 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
As of market creation, the IPO is scheduled to price on April 17 (ET). If no such IPO occurs by May 31, 2026, 11:59 PM ET, the market will resolve to "No IPO before June 2026".
Market capitalization expresses the monetary value of a company’s outstanding shares, stated in its pricing currency.
It is calculated as the total number of outstanding shares, multiplied by the official closing share price of the publicly traded class on the first trading day.
If necessary, to accurately capture the company’s total market capitalization, rather than a stock-class-specific market capitalization, the calculation will include all outstanding share classes and apply any stated conversion ratios to the publicly traded class. Where no conversion right exists, such shares will be counted at their stated outstanding amount without discount, unless official filings explicitly specify differently.
The number of outstanding shares will be determined from official company filings or disclosures (e.g., SEC filings). The closing share price on the first trading day will be determined from the primary exchange’s official listing page.
If the relevant value falls exactly between two brackets, this market will resolve to the higher range bracket.
The primary resolution source for this market will be official company filings and the primary exchange’s official listing page. The market capitalization will be determined through appropriate calculation using the total outstanding shares and the closing price from the first day of trading.
In the event of an interruption in the normal trading session on the specified company’s first day of trading (e.g., a circuit breaker or half-day), the market will resolve according to the official closing price of the abbreviated session. If no such official closing price is published, the market will resolve according to the next trading day on which an official closing price is published, treating that day as the first day of trading for the purposes of this market.
Volume
$26,612Date de fin
17 avr. 2026Marché ouvert
Apr 14, 2026, 5:05 PM ETResolver
0x69c47De9D...Kailera Therapeutics priced its upsized initial public offering at the $16 high-end on April 16, raising a record $625 million—the largest biotech IPO of 2026—implying a fully diluted valuation exceeding $2.1 billion and setting the stage for trader consensus on the 2.1B+ outcome. Shares debuted strongly on Nasdaq (KLRA) April 17, closing at $26 amid 63% first-day gains on 8 million shares traded, pushing market capitalization to $3.07 billion based on official outstanding shares. This reflects robust demand for the company's Phase 3 obesity candidate ribupatide, a once-weekly GLP-1/GIP, amid GLP-1 sector hype and open biotech IPO windows. Polymarket's skin-in-the-game crowd prices near-certainty here, though rare post-debut adjustments to filings or abbreviated trading could theoretically challenge it; settlement is expected April 20.
Résumé expérimental généré par IA à partir des données Polymarket. Ceci n'est pas un conseil de trading et ne joue aucun rôle dans la résolution de ce marché. · Mis à jour
Méfiez-vous des liens externes.
Méfiez-vous des liens externes.
Questions fréquentes